Efficacy and safety of second-line nab-paclitaxel plus gemcitabine (nab-P+GEM) after progression on first-line FOLFIRINOX in advanced pancreatic ductal adenocarcinoma (PDAC): Multicenter retrospective analysis.

Changhoon Yoo,Hyehyun Jeong,Heejung Chae,Jaekyung Cheon,Hong Jae Chon,Hyewon Ryu,Il-Hwan Kim,Jae Ho Jeong,Kyu Pyo Kim,Baek-Yeol Ryoo

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine (nab-P+GEM) after progression on first-line FOLFIRINOX in advanced pancreatic ductal adenocarcinoma (PDAC): Multicenter retrospective analysis.

2020

Changhoon Yoo
Hyehyun Jeong
Heejung Chae
Jaekyung Cheon
Hong Jae Chon
Hyewon Ryu
Il-Hwan Kim
Jae Ho Jeong
Kyu Pyo Kim
Baek-Yeol Ryoo

689Background: FOLFIRINOX is one of standard 1st-line regimens for patients (pts) with advanced PDAC. However, there is no globally established 2nd-line regimen after failure of FOLFIRINOX. Althoug...

Keywords:

FOLFIRINOX
pancreatic ductal adenocarcinoma
Internal medicine
Gemcitabine
first line
Oncology
Medicine
Nab-paclitaxel
Pathology
Regimen
second line
retrospective analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations